A comparison of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in DBA/2 and C57BL/6 inbred mice

Behavioural Pharmacology

Volumn 19, Issue 5-6, 2008, Pages 530-542

  Porter, Joseph H ^a   Walentiny, David Matthew ^a   Philibin, Scott D ^b   Vunck, Sarah A ^a   Crabbe, John C ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Alpha adrenergic; Antipsychotic drugs; C57BL 6 mice; Clozapine; DBA 2 mice; Dopamine; Drug discrimination; Serotonin

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMPHETAMINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; MEPYRAMINE; OLANZAPINE; PRAZOSIN; RISPERIDONE; RITANSERIN; SCOPOLAMINE; SEROTONIN 2 ANTAGONIST; SEROTONIN RECEPTOR; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; C57BL 6 MOUSE; COMPARATIVE STUDY; DBA 2 MOUSE; DISCRIMINATIVE STIMULUS; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG DISCRIMINATION; INBRED STRAIN; MALE; MOUSE; NONHUMAN; STRAIN DIFFERENCE; ANIMAL; BRAIN; C57BL MOUSE; DBA MOUSE; DISCRIMINATION LEARNING; DRUG ANTAGONISM; DRUG EFFECT;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; CLOZAPINE; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; RECEPTORS, DOPAMINE D2; RISPERIDONE;

EID: 58149329140     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32830cd84e     Document Type: Article

References (60)

1. Balster RL (1991). Drug abuse potential evaluation in animals. Br J Addict 86:1549-1558.
2. Bitter I, Dossenbach MR, Brook S, Feldman PD, Metcalfe S, Gagiano CA, et al. (2004). Olanzapine HGCK Study Group. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:173-180.
3. Bruhwyler J, Liégeois JF, Bergman J, Carey G, Goudie A, Taylor A, et al. (1997). JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: a review of its behavioural properties. Pharmacol Res 36:255-264.
4. Cabib S, Puglisi-Allegra S, Ventura R (2002). The contribution of comparative studies in inbred strains of mice to the understanding of the hyperactive phenotype. Behav Brain Res 130:103-109.
5. Carey GJ, Bergman J (1997). Discriminative-stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs. Psychopharmacology (Berl) 132:261-269.
6. Cole JC, Field M, Sumnall HR, Goudie AJ (2008). Potentiation of olanzapine substitution in rats discriminating clozapine by the D2/3 agonist quinpirole. Behav Pharmacol 18:185-190.
7. Crabbe JC, Phillips TJ, Buck KJ, Cunningham CL, Belknap JK (1999). Identifying genes for alcohol and drug sensitivity: recent progress and future directions. Trends Neurosci 22:173-179.
8. Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N, et al. (1997). Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl) 132:107-124.
9. DeLeon A, Patel NC, Crismon ML (2004). Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26:649-666.
10. Extance K, Goudie AJ (1981). Inter-animal olfactory cues in operant drug discrimination procedures in rats. Psychopharmacology 73:363-371.
11. Goas JA, Boston JE Jr (1978). Discriminative stimulus properties of clozapine and chlorpromazine. Pharmacol Biochem Behav 8:235-241.
12. Goudie A, Taylor A (1998). Comparative characterisation of the discriminative stimulus properties of clozapine and other antipsychotics in rats. Psychopharmacology (Berl) 135:392-400.
13. Goudie AJ, Smith JA (1999). Discriminative stimulus properties of antipsychotics. Pharmacol Biochem Behav 64:193-201.
14. Goudie AJ, Smith JA, Cole JC (2004a). Stimulus properties of the 'atypical' antipsychotic zotepine in rats: comparisons with clozapine and quetiapine. Pharmacol Biochem Behav 77:163-173.
15. Goudie AJ, Smith JA, Millan MJ (2004b). Characterization of the effects of receptor-selective ligands in rats discriminating the novel antipsychotic quetiapine. Psychopharmacology (Berl) 171:212-222.
16. Goudie AJ, Cole JC, Sumnall HR (2007). Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats. Behav Pharmacol 18:9-17.
17. Grant KA (1999). Strategies for understanding the pharmacological effects of ethanol with drug discrimination procedures. Pharmacol Biochem Behav 64:261-267.
18. Hoenicke EM, Vanecek SA, Woods JH (1992). The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. J Pharmacol Exp Ther 263:276-284.
19. Holmes A, Wrenn CC, Harris AP, Thayer KE, Crawley JN (2002). Behavioral profiles of inbred strains on novel olfactory, spatial and emotional tests for reference memory in mice. Genes Brain Behav 1:55-69.
20. Holtzman SG (1990). Discriminative stimulus effects of drugs: relationship to potential for abuse. In: Adler MW, Cowan A, editors. Modern methods in pharmacology: testing and evaluation of drugs of abuse. New York: Wiley-Liss; pp. 193-210.
21. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
22. Kelley BM, Porter JH (1997). The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats. Pharmacol Biochem Behav 57:707-719.
23. Kostowski W, Bieñkowski P (1999). Discriminative stimulus effects of ethanol: neuropharmacological characterization. Alcohol 17:63-80.
24. Lewis S, Lieberman J (2008). CATIE and CUtLASS: can we handle the truth? Br J Psychiatry 192:161-163.
25. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al.; CATIE Investigators (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600-610.
26. Meltzer HY, Matsubara S, Lee JC (1989). The ratios of serotonin 2 and dopamine 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25:390-392.
27. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159-1172.
28. Meltzer HY, Bobo WV, Roy A, Jayhatilake K, Chen Y, Ertugrul A, et al. (2008). A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 69:274-285.
29. Meyer JM (2007). Antipsychotic safety and efficacy concerns. J Clin Psychiatry 68 (Suppl 14):20-26.
30. Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, et al. (1998a). S 16924 [(R)-2-(1-2-[2,3-dihydro-benzo(1,4) dioxin-5-yloxy]-ethyl-pyrrolidin-3yl)-1-(4-fluoro-phenyl)-ethanone], a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptor and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exp Ther 286:1341-1355.
31. Millan MJ, Schreiber R, Dekeyne A, Rivet JM, Bervoets K, Mavridis M, et al. (1998b). S 16924 [(R)-2-1-[2,3-dihydro-benzo(1,4) dioxin-5-yloxy]-ethyl-pyrrolidin-3yl)-1-(4-fluoro-phenyl)-ethanone], a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 286: 1356-1373.
32. Millan MJ, Gobert A, Girardon S, Dekeyne A (1999). Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs. dopamine and noradrenaline. Eur J Pharmacol 364:147-150.
33. Millan MJ, Brocco M, Rivet JM, Audinot V, Newman-Tancredi A, Maiofiss L, et al. (2000). S18327 (1-2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1- yl]ethyl3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents. J Pharmacol Exp Ther 292: 54-66.
34. Nielsen EB (1988). Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology (Berl) 94:115-118.
35. Oliverio A, Castellano C (1981). Behavioral effects of opiates: a pharmaco-genetic analysis. Curr Dev Psychopharmacol 6:45-64.
36. Philibin SD, Prus AJ, Pehrson AL, Porter JH (2005). Serotonin receptor mechanisms mediate the discriminative stimulus properties of the atypical antipsychotic clozapine in C57BL/6 mice. Psychopharmacology (Berl) 180: 49-56.
37. Philibin SD, Walentiny DM, Prus AJ, Meltzer HY, Porter JH (2006). Clozapine drug discrimination in C57BL/6 mice detects antipsychotic agents based on serotonergic or adrenergic antagonist actions. Program No. 768.22. 2006 Abstract Viewer/Itinerary Planner. Atlanta, GA: Society for Neuroscience.
38. Porter JH, Varvel SA, Vann RE, Philibin SD, Wise LE (2000). Clozapine discrimination with a low training dose distinguishes atypical from typical antipsychotic drugs in rats. Psychopharmacology (Berl) 149:189-193.
39. Porter JH, Prus AJ, Vann RE, Varvel SA (2005). Discriminative stimulus properties of the atypical antipsychotic clozapine and the typical antipsychotic chlorpromazine in a three-choice drug discrimination procedure in rats. Psychopharmacology (Berl) 178:67-77.
40. Prus AJ, Baker LE, Meltzer HY (2004). Discriminative stimulus properties of 1.25 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms. Pharmacol Biochem Behav 77:199-208.
41. Prus AJ, Philibin SD, Pehrson AL, Porter JH (2006). Discriminative stimulus properties of the atypical antipsychotic drug clozapine in rats trained to discriminate 1.25 mg/kg clozapine vs. 5.0 mg/kg clozapine vs. vehicle. Behav Pharmacol 17:185-194.
42. Puglisi-Allegra S, Cabib S (1997). Psychopharmacology of dopamine: the contribution of comparative studies in inbred strains of mice. Prog Neurobiol 51:637-661.
43. Puglisi-Allegra S, Kempf E, Cabib S (1990). Role of genotype in the adaptation of the brain dopamine system to stress. Neurosci Biobehav Rev 14:523-528.
44. Riley B, Kendler KS (2006). Molecular genetic studies of schizophrenia. Eur J Hum Genet 14:669-680.
45. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57-73.
46. Shannon EE, Purdy RH, Grant KA (2005a). Discriminative stimulus effects of 5.6 mg/kg pregnanolone in DBA/2J and C57BL/6J inbred mice. Alcohol 37:35-45.
47. Shannon EE, Porcu P, Purdy RH, Grant KA (2005b). Characterization of the discriminative stimulus effects of the neuroactive steroid pregnanolone in DBA/2J and C57BL/6J inbred mice. J Pharmacol Exp Ther 314:675-585.
48. Shelton KL (2004). Substitution profiles of N-methyl-D- aspartate antagonists in ethanol-discriminating inbred mice. Alcohol 34:165-175.
49. Shelton KL, Balster RL (2004). Effects of abused inhalants and GABA-positive modulators in dizocilpine discriminating inbred mice. Pharmacol Biochem Behav 79:219-228.
50. Shelton KL, Grant KA (2002). Discriminative stimulus effects of ethanol in C57BL/6J and DBA/2J inbred mice. Alcohol Clin Exp Res 26:747-757.
51. Singh SM, Treadwell J, Kleiber ML, Harrison M, Uddin RK (2007). Analysis of behavior using genetical genomics in mice as a model: from alcohol preferences to gene expression differences. Genome 50:877-897.
52. Smith JA, Goudie AJ (2002). Discriminative stimulus properties in rats of the novel antipsychotic quetiapine. Exp Clin Psychopharmacol 10:376-384
53. Stolerman IP, Naylor C, Elmer GI, Goldberg SR (1999). Discrimination and self-administration of nicotine by inbred strains of mice. Psychopharmacology 141:297-306.
54. Sullivan PF, Kendler KS, Neale MC (2003). Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 60: 1187-1192.
55. Sun J, Kuo PH, Riley BP, Kendler KS, Zhao Z (2008). Candidate genes for schizophrenia: a survey of association studies and gene ranking. Am J Med Genet B Neuropsychiatr Genet [Epub ahead of print].
56. Tamminga CA (2002). Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109:411-420.
57. Tang AH, Franklin SR, Himes CS, Smith MW, Tenbrink RE (1997). PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties. J Pharmacol Exp Ther 281:440-447.
58. Wahlsten D, Bachmanov A, Finn DA, Crabbe JC (2006). Stability of inbred mouse strain differences in behavior and brain size between laboratories and across decades. Proc Natl Acad Sci 103:16364-16369.
59. Wiley JL, Porter JH (1992). Serotonergic drugs do not substitute for clozapine in clozapine-trained rats in a two-lever drug discrimination procedure. Pharmacol Biochem Behav 43:961-965.
60. Zocchi A, Orsini C, Cabib S, Puglisi-Allegra S (1998). Parallel strain-dependent effect of amphetamine on locomotor activity and dopamine release in the nucleus accumbens: an in vivo study in mice. Neuroscience 82:521-528.